Suppr超能文献

微创手术改善心源性休克患者左心室辅助装置手术的预后。

Minimally invasive surgery improves outcome of left ventricular assist device surgery in cardiogenic shock.

作者信息

Wert Leonhard, Chatterjee Anamika, Dogan Günes, Hanke Jasmin S, Boethig Dietmar, Tümler Kirstin A, Napp L Christian, Berliner Dominik, Feldmann Christina, Kuehn Christian, Martens Andreas, Shrestha Malakh L, Haverich Axel, Schmitto Jan D

机构信息

Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

出版信息

J Thorac Dis. 2018 Jun;10(Suppl 15):S1696-S1702. doi: 10.21037/jtd.2018.01.27.

Abstract

BACKGROUND

Left ventricular assist device (LVAD) (HVAD, Medtronic, Minneapolis, MN, USA) implantation is already a widely accepted treatment option for end-stage heart failure (HF) but also still considered as a rescue therapy for patients suffering from cardiogenic shock. Standard LVAD implantation techniques are often associated with high mortality rates and can result in severe complications, like bleeding or right heart failure (RHF). The aim of our study was to assess the outcome of Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 1 patients (so called "crash and burn" patients) undergoing a LVAD implantation by standard or less invasive surgery.

METHODS

We performed a retrospective evaluation of the 1-year outcome of 32 consecutive HF patients in cardiogenic shock, who underwent LVAD implantation in our institution. A total of 32 INTERMACS 1 patients were emergently operated. Fourteen patients (group A) were operated by using the "Hannover-VAD-technique", which is widely known to be less invasive (upper hemisternotomy and a left-sided anterolateral thoracotomy). In contrast, 18 patients (group B) were implanted with LVAD by using the standard technique (full sternotomy). The primary endpoint was survival after 1 year without device-related re-operations. Secondary endpoints included combined analyses of rates of RHF, respiratory failure and bleeding during the trial period.

RESULTS

Baseline characteristics were similar in both groups. Survival after 1 year was higher in group A (69.7% 50.0%). Technique-related adverse events (AEs) were also lower in the minimally invasive group, including a lower RHF (35.7% 61.1%) and of further postoperative bleeding requiring surgery (14.3% 33.3%).

CONCLUSIONS

LVAD surgery in INTERMACS 1 patients is associated with remarkably good outcome considering the already very high mortality of those patients, and compared to previously reported surgical outcomes. Our study indicates that minimally invasive LVAD implantation in cardiogenic shock decreases mortality and the incidence of postoperative AEs.

摘要

背景

左心室辅助装置(LVAD)(HeartWare心室辅助系统,美敦力公司,明尼阿波利斯,明尼苏达州,美国)植入术已成为终末期心力衰竭(HF)广泛接受的治疗选择,但仍被视为心源性休克患者的抢救治疗方法。标准的LVAD植入技术常伴随着高死亡率,并可能导致严重并发症,如出血或右心衰竭(RHF)。我们研究的目的是评估通过标准或微创外科手术进行LVAD植入的机构间机械辅助循环支持注册研究(INTERMACS)1级患者(即所谓的“濒死”患者)的预后。

方法

我们对在我院接受LVAD植入的32例连续性心源性休克HF患者的1年预后进行了回顾性评估。共有32例INTERMACS 1级患者接受了急诊手术。14例患者(A组)采用“汉诺威VAD技术”进行手术,该技术以微创性广为人知(上半胸骨切开术和左侧前外侧开胸术)。相比之下,18例患者(B组)采用标准技术(全胸骨切开术)植入LVAD。主要终点是1年后无装置相关再次手术的生存率。次要终点包括试验期间RHF、呼吸衰竭和出血发生率的综合分析。

结果

两组的基线特征相似。A组1年后的生存率更高(69.7%对50.0%)。微创组的技术相关不良事件(AE)也更低,包括较低的RHF发生率(35.7%对61.1%)和需要手术的进一步术后出血发生率(14.3%对33.3%)。

结论

考虑到INTERMACS 1级患者本已很高的死亡率,与先前报道的手术结果相比,LVAD手术的预后非常好。我们的研究表明,在心源性休克患者中进行微创LVAD植入可降低死亡率和术后AE的发生率。

相似文献

引用本文的文献

本文引用的文献

1
Minimally-invasive LVAD Implantation: State of the Art.微创左心室辅助装置植入术:当前技术水平
Curr Cardiol Rev. 2015;11(3):246-51. doi: 10.2174/1573403x1103150514151750.
3
Increase in left ventricular assist device thrombosis.左心室辅助装置血栓形成增加。
N Engl J Med. 2014 Apr 10;370(15):1463-4. doi: 10.1056/NEJMc1401768.
7
Major bleeding during HeartMate II support.HeartMate II 辅助治疗期间发生大出血。
J Am Coll Cardiol. 2013 Dec 10;62(23):2188-96. doi: 10.1016/j.jacc.2013.05.089. Epub 2013 Aug 28.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验